BUZZ Sessions

소수 인원의 활발한 논의 및 적극적인 대화가 문제 해결로 연결되는 솔루션 및 특정 분야 에서의 향후 협력 체제로 연결됩니다.

BuzZ Session 소개

PepTalk의 BuzZ Session에서는 업스트림 공정 단백질 발현·생산으로부터 다운스트림 공정 스케일업·제조에 이르기까지 중요하고 흥미로운 토픽에 대해 대표자가 집중적으로 자극적인 토론을 진행합니다. 토론 테마로 공통의 관심을 가지고 있는 폭넓은 분야의 과학자가 참가하며, 사회자의 진행으로 브레인스토밍 및 양방향 문제 해결 등에 주력합니다.

이 포럼은 단백질 관련 문제에 대해 공개 논의하는 장소이며, 판매의 기회가 아닙니다. 특히 이 분과 그룹은 과학자 간 양방향 토론 장소이며, 기업 및 제품에 관한 논의가 아닙니다. 토픽은 1개의 단백질 분야로 한정할 수도 있고, 일련의 컨퍼런스 의제에 걸친 문제를 채택할 수도 있습니다. 사회자는 의제 분야에 정통하고, 토론을 집중적·생산적으로 진행할 수 있는 인물입니다. BuzZ Session은 대면 형식으로만 진행됩니다.


1월 16일(화):오후 2:15~4:15

Intelligent Antibody Discovery Part 1

BuzZ Table: Challenges Faced with Screening Biologics for Function
Moderator:
Elizabeth England, PhD, Associate Director, Biologics Engineering, AstraZeneca

  • Types of assays used for functional screening
  • Biochemical function versus cell-based function
  • Sample types and modalities
  • Use of disease relevant cells

 

BuzZ Table: T Cell Receptors as an Emerging Modality
Moderator: Govinda Sharma, PhD, Founder, Immfinity Biotechnologies

  • What's the difference? Differing design principles between cell-based and soluble TCR therapeutics
  • Can TCR-T cell therapies fill in the gaps that CAR-T cell therapies are struggling to address?
  • Target selection for TCR development. Choosing the best HLA allele, finding the right peptides.
  • Manufacturing in soluble and cell-based TCR therapeutics. Can we learn from antibody and CAR-T manufacturing by analogy?
  • Improving predictive ML/AI tools for modeling TCR interactions. What are the current limitations?

BuzZ Table: When will Computationally Designed Proteins Become Common in the Clinic? 
Moderator:
Erik Procko, PhD, Director, Discovery, Cyrus Biotechnology; Adjunct Professor, University of Illinois, Urbana

  • Current status: high yields, high stability, fast development, complex functionality 
  • Stumbling blocks: immunogenicity prediction. need better ex vivo assays to assess immunogenicity before going into humans 
  • Can de novo protein binders compete with monoclonal antibodies? 

Developability of Bispecific Antibodies

BuzZ Table: Enhancing Bispecific T Cell Engager Discovery, Potency, Safety, and Developability with Machine Learning and Mammalian Display
Moderator: Matthew P. Greving, PhD, Vice President & Head, Machine Learning & Platform Technologies, iBio, Inc.

  • Improving discovery productivity and diversity for the bispecific T Cell engager's immune cell arm
  • New advancements in the discovery of difficult tumor-antigen arm targets and epitopes 
  • T Cell engager safety enhancement with ML-derived mammalian display libraries and conditional activation
  • Large-scale bispecific activity and developability screening with mammalian display

BuzZ Table: Which Formats are Most Developable
Moderator: G. Jonah Rainey, PhD, Senior Director, Protein Engineering, Eli Lilly and Company

Characterization of Biotherapeutics

BuzZ Table: Leveraging LinkedIn for Scientific Advancement: Optimizing Digital Presence, Building Networks, Driving Innovation
Moderator: Nandini Kashyap, M. Pharm, Senior Director, Conferences, and Social Media Strategy, Cambridge Innovation Institute

  • Strategies for Crafting an Impactful digital persona
  • Building global networks and collaborations
  • Driving innovation and advancement through thought leadership

Viral Vector Engineering & Scale-Up Considerations

BuzZ Table: Recent Advancements with Viral Vectors
Moderator: Lizz Carey, Senior Scientist, Vaccine Process Development, Merck

  • Applications to gene therapy
  • Emerging technologies
  • Challenges and ethical considerations
  • CRISPR and viral vectors

BuzZ Table: Strategies for Optimizing AAV Production
Moderator: Kathy Ngo, PhD, Associate Director, Cell Engineering, CHO Plus

  • Engineering better clones and pools
  • Vector design strategies and TGE optimization
  • Media and feed development for AAV production
  • Case studies

Cell Line Optimization

BuzZ Table: Automation in Cell Line Optimization
Moderator: Vel Murugan, PhD, MBA, Associate Research Professor and Director, Biodesign Institute, Arizona State University

  • Role of gene synthesis technologies
  • Automation in cell engineering
  • High throughput culturing environments
  • Functional genomics in cell engineering and optimization

BuzZ Table: Prokaryotic Innovation
Moderator: Simon A. Messing, PhD, Scientist II, Frederick National Lab & Protein Expression Lab, Leidos Biomedical Research, Inc.

  • E.coli has been the dominant prokaryotic recombinant expression system for 50 years
  • Improvements in use of chaperones and temperature in E.coli production
  • New expression line Vibrio Natriegens

1월 19일(금):오전 7:45~8:45(콘티넨탈 브렉퍼스트 첨부)

Intelligent Antibody Discovery Part 2

BuzZ Table: Intelligent Antibody Discovery & Engineering
Moderator: Christopher R. Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada

  • What is the future of AI in Ab Discovery?
  • What data are we currently missing to push the field further?
  • Where should we focus? Discovery vs Optimization vs Manufacturing

BuzZ Table: Applications of Molecular Dynamics for Machine Learning
Moderator: Darcy Davidson, PhD, Structural and Computational Biologist, Genentech

  • Using MD for training data for ML, introducing physics into ML
  • Generalizing beyond training data for ML
  • Experimental data vs QM calculations as training data
  • What are people's expectations and aspirations for ML-augmented simulations?

Safety & Efficacy of Bispecific Antibodies, ADCs and Combination Therapy

BuzZ Table: Strategies to Improve T Cell Responses to Treat Patients with Solid Tumors
Moderator: Mark L. Chiu, PhD, CSO, Tavotek Biotherapeutics

  • Engineering higher selectivity to solid tumor tissues
  • Breaking the barriers to get into solid tumors
  • Handling dysfunctional immune cells in the solid tumor microenvironment

BuzZ Table: Challenges in Developing Immune Modulating Therapeutics for Autoimmune Diseases-Will the Opposite (Inhibition of the Activated Immune System) from an Oncology Strategy (Activation of the Immune System) Work?
Moderator: Rakesh Dixit, PhD, President & CEO, Bionavigen

  • To treat autoimmune disease, potential benefits in enhancing (agonism) immune checkpoint inhibitor (ICI) signaling, e.g., CTLA4, PD1, LAG3, TIM3, and TIGIT
  • Alternatively, inhibition (antagonism) of immune activation by OX-40, GITRR, and CD-137 may relieve autoimmune diseases
  • Discussion on inhibitory immune checkpoint homeostasis in controlling infections and defenses against cancers
  • Challenges of developing agents that promote defenses against autoreactive T cells vs. activation of cytotoxic T cells against cancers?
  • Long-term safety risks in activating inhibitory ICI targets or antagonizing immune activation pathways in promoting cancers, chronic immune suppression, and infections

Characterizing Protein Aggregates & Impurities

BuzZ Table: Beyond Host-Cell Protein ELISA
Moderator: Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences (BOKU)

  • Understanding host cell protein profiles with modern proteomics tools
  • Are the limits state-of-the-art and which proteins are relevant?
  • Fast methods for host cell protein profiling

Non-Viral Vector Engineering

BuzZ Table: Non-Viral Methods for Protein Production and Delivery
Moderator: Lauren E. Woodard, PhD, Assistant Professor, Nephrology, Vanderbilt University

  • Transposons, integrases, and other integrating vectors
  • Exosomes and exosome loading
  • In vitro and in vivo delivery considerations
  • Intellectual property navigation

BuzZ Table: Viral Vectors vs Non-Viral Vectors: Which Is Optimal for Your Needs?
Moderator: Pranav Sharma, PhD, Founder & CSO, R&D, Xosomix

  • Efficacy and Safety Profiles
  • Scalability and Manufacturing Challenges
  • Targeted Delivery and Tissue Specificity
  • Clinical Translation and Therapeutic Applications

Recombinant Protein Expression & Production

BuzZ Table: Protein Interest Group (PIG) - Online Community of Protein Scientists
Moderator: Oleg Brodsky, Senior Principal Scientist, Structural Biology & Protein Sciences, Pfizer Inc.

  • What is the Protein Interest Group (PIG), and what it isn’t
  • How do we share our knowledge and experiences pre-competitively, aside from published manuscripts
  • Logistics, topics covered, group remit
  • How to become a member

BuzZ Table: Common Issues with Transient Protein Production
Moderator: Richard Altman, MS, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific
Moderator: Henry C. Chiou, PhD, Senior Director General Manager, Biosciences, Thermo Fisher Scientific

  • What are the current challenges to transient protein production?
  • How do we optimize the whole protein expression workflow process?
  • How can we maintain volumetric yields while scaling transient expression up or down?
  • What cell line(s) should we use and when?
  • What parameters can impact the quality or physical attributes of transiently produced proteins?

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

해당 컨퍼런스는 종료되었습니다.
Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English_



Premier Sponsor

UnchainedLabs

프로그램

Antibody Discovery & Engineering Stream항체 탐색·엔지니어링
 
Bispecific Antibody Development Stream이중특이성항체 탐색
 
Characterization of Biotherapeutics & Vaccines Stream생물학적 제제·백신의 특성 평가
 
Vector Design & Delivery Stream벡터의 설계와 전달
 
Biotherapeutic Expression & Production Stream생물학적 제제의 발현과 생산
 
Stream트레이닝 세미나
 
Catalog Download
Catalog